YILDIRIM, H. Ç. Et Al. 2024. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer. MEDICINE , no.30 .

YILDIRIM, H. Ç., Buyukkor, M., KAVGACI, G., ŞAHİN ÇELİK, B., BİR YÜCEL, K., DURSUN, B., ... Chalabiyev, E.(2024). The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer. MEDICINE , no.30.

YILDIRIM, HASAN Et Al. "The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer," MEDICINE , no.30, 2024

YILDIRIM, HASAN Ç. Et Al. "The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer." MEDICINE , no.30, 2024

YILDIRIM, H. Ç. Et Al. (2024) . "The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer." MEDICINE , no.30.

@article{article, author={HASAN ÇAĞRI YILDIRIM Et Al. }, title={The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer}, journal={MEDICINE}, year=2024}